{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T05:26:45Z","timestamp":1773552405553,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02782-4","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:02:07Z","timestamp":1708452127000},"page":"1305-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives"],"prefix":"10.1007","volume":"41","author":[{"given":"Rebecca","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Samples-Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-1840","authenticated-orcid":false,"given":"Keri M.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan L.","family":"Whatley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane B.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185\u20138.","journal-title":"Nat Genet"},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","volume":"12","author":"U Petriti","year":"2023","unstructured":"Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review and meta-analysis. Syst Rev. 2023;12:5.","journal-title":"Syst Rev"},{"key":"2782_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/345270","volume":"2014","author":"A Percy","year":"2014","unstructured":"Percy A. Rett syndrome: coming to terms with treatment. Adv Neurosci. 2014;2014: 345270.","journal-title":"Adv Neurosci"},{"key":"2782_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2020-000731","volume":"4","author":"C Fu","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, et al. Multisystem comorbidities in classic Rett syndrome: a scoping review. BMJ Paediatr Open. 2020;4:e000731.","journal-title":"BMJ Paediatr Open"},{"key":"2782_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","volume":"55","author":"KJ Motil","year":"2012","unstructured":"Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55:292\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MPG.0b013e318073cbf7","volume":"45","author":"WH Oddy","year":"2007","unstructured":"Oddy WH, Webb KG, Baikie G, et al. Feeding experiences and growth status in a Rett syndrome population. J Pediatr Gastroenterol Nutr. 2007;45:582\u201390.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1358\/dof.2021.46.1.3208246","volume":"46","author":"BE Collins","year":"2021","unstructured":"Collins BE, Trofinetide NJL. Glycine-proline-glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome. Drugs Fut. 2021;46:29\u201341.","journal-title":"Drugs Fut"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase\u00a03 study. Nat Med. 2023;29:1468\u201375.","journal-title":"Nat Med"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","volume":"11","author":"ED Marsh","year":"2023","unstructured":"Marsh ED, Beisang A, Buie T, Benke TA, Gaucher B, Motil KJ. Recommendations for the management of diarrhea with trofinetide use in Rett syndrome. Expert Opin Orphan Drugs. 2023;11:1\u20138.","journal-title":"Expert Opin Orphan Drugs"},{"key":"2782_CR10","doi-asserted-by":"crossref","unstructured":"Percy AK, Neul JL, Benke TA, et al, editors. Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study. IRSF Rett Syndrome Scientific Meeting, June 5\u20137, 2023; Nashville, TN.","DOI":"10.1016\/j.medj.2024.05.018"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1212\/WNL.0000000000201897","volume":"100","author":"A Percy","year":"2023","unstructured":"Percy A, Ryther R, Marsh E, et al. Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4\u00a0years of age. Neurology. 2023;100:1378.","journal-title":"Neurology"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346.","journal-title":"Pediatr Neurol"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u201325.","journal-title":"Neurology"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"FRD43","DOI":"10.2217\/frd-2023-0011","volume":"3","author":"KJ Motil","year":"2023","unstructured":"Motil KJ, Beisang A, Benke TA, Gaucher B, Abler V, Pichard D. Recommendations for managing diarrhea from trofinetide use in individuals with Rett syndrome: a plain language summary. Future Rare Dis. 2023;3:FRD43.","journal-title":"Future Rare Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02782-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:20:00Z","timestamp":1731370800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02782-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02782-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors thank all participants in the LAVENDER, LILAC, and DAFFODIL trials and their caregivers. Rebecca Moore, Joshua Poulsen, and Holly Simmons are parents of children who participated in the LAVENDER and LILAC trials and have participated in advisory board meetings sponsored by Acadia Pharmaceuticals Inc. Lindsay Reardon is a parent of a child who participated in the DAFFODIL trial and has participated in advisory board meetings sponsored by Acadia Pharmaceuticals Inc. Candice Samples-Morris is a parent of a child who participated in the LAVENDER and LILAC trials, has participated in advisory board meetings sponsored by Acadia Pharmaceuticals Inc., and has spoken on behalf of Acadia Pharmaceuticals Inc. Keri M. Ramsey and Meagan L. Whatley participated in the LAVENDER, LILAC, and DAFFODIL trials as research nurse coordinators for their study site. Jane B. Lane participated in the LAVENDER, LILAC, and DAFFODIL trials as a research nurse manager for the study site and is a consultant for Acadia Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based upon caregiver interviews and not on new clinical data with human participants or animals, so it did not require ethics committee approval. All authors met the criteria of the International Committee of Medical Journal Editors for this manuscript, take responsibility for the integrity of the work, and gave their final approval of the final draft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}